Sigma-Aldrich Announces CE Mark Certification
Sigma-Aldrich Corporation is pleased to announce the certification of its Cell Culture and hematology & histology products with a CE Mark, making them eligible for sale in the European Union.
Under the European IVD Directive, certain products must meet regulatory requirements in order to qualify for sale and distribution in the European Union. The CE Marking indicates that a product complies with EU safety, environmental, and quality standards. Sigma-Aldrich has satisfactorily completed the testing and registration required to obtain CE Marking for approximately 400 of its products in the Cell Culture and Hematology & Histology product lines.
Eight product families in the Hematology & Histology line, including 250 products, have received the CE Marking, including Routine and Special Hematology stains, Routine and Special Histology stains, Histopaque Cell Separation media, Cytochemical stains, Cytology stains, and Histology stains.
The Cell Culture line received CE marking for 17 product families that include 150 products. Product families given CE Markings were Liquid Media with or without glutamine and sodium pyruvate, Concentrated Liquid Media, Salt Solutions with and without sodium bicarbonate, trypsin and penicillin solutions, Powered Media with and without glutamine, Powdered Salt Mixtures, Amniocyte Media, Bone Marrow Media, BSK-H Media, Fetal Bovine Serum, Cytogenics reagents and Supplements, L15 Leibovitz Media and Peripheral Blood Medica.
"Sigma-Aldrich's commitment to quality and safety are second to none," said Marilyn Baltz, PhD, Regulatory Site Manager at Sigma-Aldrich. "Obtaining the CE Mark confirms the excellence of our products and secures our presence in the European Union marketplace."
Organizations
Other news from the department research and development
These products might interest you

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection

Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines

CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy

Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Antisense Pharma Receives Approval for Clinical Studies in South Korea and Taiwan in Malignant Brain Tumors - With this approval, the Southeast Asian health agencies KFDA and TFDA have paved the way for the implementation of the pivotal Phase III study SAPPHIRE with the TGF-β2 inhibitor trabedersen
Queen's University Belfast makes significant cancer breakthrough
McKinsey: By 2010 Industrial Biotechnology Will Account for 10 Percent of Sales within the Chemical Industry - New Data About Growth in Industrial Biotech Sector at World Congress
MedMira Builds European Sales Infrastructure
Sanofi-aventis and Oxford Biomedica report encouraging TroVax Phase II results in metastatic renal cancer
Wyeth licenses drug targets from osteoporosis collaboration with Galapagos
Merck and Ono Pharmaceutical Form Collaborations to Develop Oral Multiple Sclerosis Drug and Cancer Immunotherapy
Evidence grows that melanoma drugs benefit some lung cancer patients - Many patients with BRAF-mutant cancers benefit from treatment with BRAF inhibitors, European researchers report at ELCC
Invitrogen Acquires Products and Technology Rights of PanVera LLC from Vertex Pharmaceuticals
Unusual protein modification involved in muscular dystrophy, cancer
